Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/83024
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPodurgiel, S.en
dc.contributor.authorCollins-Praino, L.en
dc.contributor.authorYohn, S.en
dc.contributor.authorRandall, P.en
dc.contributor.authorRoach, A.en
dc.contributor.authorLobianco, C.en
dc.contributor.authorSalamone, J.en
dc.date.issued2013en
dc.identifier.citationPharmacology Biochemistry and Behavior, 2013; 105:105-111en
dc.identifier.issn0091-3057en
dc.identifier.issn1873-5177en
dc.identifier.urihttp://hdl.handle.net/2440/83024-
dc.description.abstractSafinamide is an α-aminoamide derivative that is currently in Phase III clinical trial development as an add-on therapy to levodopa or dopamine agonists for patients with Parkinson's disease. Safinamide is a monoamine oxidase B inhibitor with additional non-dopaminergic actions. The present experiments were performed to evaluate the ability of safinamide to attenuate parkinsonian motor impairments using the tremulous jaw movement model, an animal model of parkinsonian tremor. In rats, tremulous jaw movements can be induced with dopamine (DA) antagonists, DA depletion, and cholinomimetics, and can be reversed by various antiparkinsonian drugs, including L-DOPA, DA agonists, anticholinergics and adenosine A2A antagonists. In these present experiments, tremulous jaw movements were induced with the anticholinesterase galantamine (3.0mg/kg IP), the muscarinic agonist pilocarpine (0.5mg/kg IP), and the dopamine D2 antagonist pimozide (1.0mg/kg IP). Safinamide significantly reduced the number of tremulous jaw movements induced by galantamine, pilocarpine, and pimozide, with consistent effects across all three drugs at a dose range of 5.0-10.0mg/kg. The results of this study support the use of safinamide as a treatment for parkinsonian tremor.en
dc.description.statementofresponsibilitySamantha Podurgiel, Lyndsey E. Collins-Praino, Samantha Yohn, Patrick A. Randall, Arthur Roach, Christophe Lobianco, John D. Salamoneen
dc.language.isoenen
dc.publisherPergamon-Elsevier Science Ltden
dc.rights© 2013 Elsevier Inc. All rights reserved.en
dc.subjectParkinson's disease; MAO; Dopamine; Acetylcholine; Muscarinic; Alzheimer's diseaseen
dc.titleTremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremoren
dc.typeJournal articleen
dc.identifier.rmid0020137244en
dc.identifier.doi10.1016/j.pbb.2013.01.015en
dc.identifier.pubid14969-
pubs.library.collectionAnatomical Sciences publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidCollins-Praino, L. [0000-0002-4380-7600]en
Appears in Collections:Anatomical Sciences publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.